The Cognitive decline in Older Patients with End stage renal disease (COPE) study – rationale and design

References

• Pippias M, Stel VS, Abad Diez JM, et al. Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA Registry Annual Report. Clin Kidney J 2015;8:248-61
   PubMed Web of Science ®Google Scholar
• Saran R, Li Y, Robinson B, et al. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2015;66:Svii, S1-S305
   PubMed Web of Science ®Google Scholar
• Couchoud C, Labeeuw M, Moranne O, et al. A clinical score to predict 6-month prognosis in elderly patients starting dialysis for end-stage renal disease. Nephrol Dial Transplant 2009;24:1553-61
   PubMed Web of Science ®Google Scholar
• Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv Chron Kidney Dis 2008;15:123-32
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Tighiouart H, Scott TM, et al. Frequency of and risk factors for poor cognitive performance in hemodialysis patients. Neurology 2013;80:471-80
   PubMed Web of Science ®Google Scholar
• Kurella M, Covinsky KE, Collins AJ, Chertow GM. Octogenarians and nonagenarians starting dialysis in the United States. Ann Intern Med 2007;146:177-83
   PubMed Web of Science ®Google Scholar
• Verberne WR, Geers AB, Jellema WT, et al. Comparative survival among older adults with advanced kidney disease managed conservatively versus with dialysis. Clin J Am Soc Nephrol 2016;11:633-40
   PubMed Web of Science ®Google Scholar
• Chandna SM, Schulz J, Lawrence C, et al. Is there a rationale for rationing chronic dialysis? A hospital based cohort study of factors affecting survival and morbidity. BMJ (Clin Res Ed) 1999;318:217-23
   PubMed Web of Science ®Google Scholar
• Hussain JA, Mooney A, Russon L. Comparison of survival analysis and palliative care involvement in patients aged over 70 years choosing conservative management or renal replacement therapy in advanced chronic kidney disease. Palliat Med 2013;27:829-39
   PubMed Web of Science ®Google Scholar
• Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150
   Web of Science ®Google Scholar
• Griva K, Stygall J, Hankins M, et al. Cognitive impairment and 7-year mortality in dialysis patients. Am J Kidney Dis 2010;56:693-703
   PubMed Web of Science ®Google Scholar
• Kalirao P, Pederson S, Foley RN, et al. Cognitive impairment in peritoneal dialysis patients. Am J Kidney Dis 2011;57:612-20
   PubMed Web of Science ®Google Scholar
• Murray AM, Tupper DE, Knopman DS, et al. Cognitive impairment in hemodialysis patients is common. Neurology 2006;67:216-23
   PubMed Web of Science ®Google Scholar
• Sehgal AR, Grey SF, DeOreo PB, Whitehouse PJ. Prevalence, recognition, and implications of mental impairment among hemodialysis patients. Am J Kidney Dis 1997;30:41-9
   PubMed Web of Science ®Google Scholar
• Bowling CB, O’Hare AM. Managing older adults with CKD: individualized versus disease-based approaches. Am J Kidney Dis 2012;59:293-302
   PubMed Web of Science ®Google Scholar
• Swidler MA. Geriatric renal palliative care. J Gerontol Biol Med Sci 2012;67:1400-9
   PubMed Web of Science ®Google Scholar
• Bugnicourt JM, Godefroy O, Chillon JM, et al. Cognitive disorders and dementia in CKD: the neglected kidney–brain axis. J Am Soc Nephrol 2013;24:353-63
   PubMed Web of Science ®Google Scholar
• Kallenberg MH, Kleinveld HA, Dekker FW, et al. Functional and cognitive impairment, frailty, and adverse health outcomes in older patients reaching ESRD – a systematic review. Clin J Am Soc Nephrol 2016;11:1624-39
   PubMed Web of Science ®Google Scholar
• Watanabe K, Watanabe T, Nakayama M. Cerebro-renal interactions: impact of uremic toxins on cognitive function. Neurotoxicology 2014;44:184-93
   PubMed Web of Science ®Google Scholar
• Madero M, Gul A, Sarnak MJ. Cognitive function in chronic kidney disease. Semin Dial 2008;21:29-37
   PubMed Web of Science ®Google Scholar
• Elias MF, Dore GA, Davey A. Kidney disease and cognitive function. Contrib Nephrol 2013;179:42-57
   PubMed Web of Science ®Google Scholar
• Attwell D, Buchan AM, Charpak S, et al. Glial and neuronal control of brain blood flow. Nature 2010;468:232-43
   PubMed Web of Science ®Google Scholar
• Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9:689-701
   PubMed Web of Science ®Google Scholar
• Ikram MA, Vernooij MW, Hofman A et al. Kidney function is related to cerebral small vessel disease. Stroke 2008;39:55-61
   PubMed Web of Science ®Google Scholar
• Vogels SC, Emmelot-Vonk MH, Verhaar HJ, Koek HL. The association of chronic kidney disease with brain lesions on MRI or CT: a systematic review. Maturitas 2012;71:331-6
   PubMed Web of Science ®Google Scholar
• Kuriyama N, Mizuno T, Ohshima Y, et al. Intracranial deep white matter lesions (DWLs) are associated with chronic kidney disease (CKD) and cognitive impairment: a 5-year follow-up magnetic resonance imaging (MRI) study. Arch Gerontol Geriatr 2013;56:55-60
   PubMed Web of Science ®Google Scholar
• Khatri M, Wright CB, Nickolas TL, et al. Chronic kidney disease is associated with white matter hyperintensity volume: the Northern Manhattan Study (NOMAS). Stroke 2007;38:3121-6
   PubMed Web of Science ®Google Scholar
• Thompson CS, Hakim AM. Living beyond our physiological means: small vessel disease of the brain is an expression of a systemic failure in arteriolar function: a unifying hypothesis. Stroke 2009;40:e322-30
   PubMed Web of Science ®Google Scholar
• van Beek AH, Claassen JA, Rikkert MG, Jansen RW. Cerebral autoregulation: an overview of current concepts and methodology with special focus on the elderly. J Cerebr Blood Flow Metabol 2008;28:1071-85
   PubMed Web of Science ®Google Scholar
• Gruhn N, Larsen FS, Boesgaard S, et al. Cerebral blood flow in patients with chronic heart failure before and after heart transplantation. Stroke 2001;32:2530-3
   PubMed Web of Science ®Google Scholar
• Mankovsky BN, Piolot R, Mankovsky OL, Ziegler D. Impairment of cerebral autoregulation in diabetic patients with cardiovascular autonomic neuropathy and orthostatic hypotension. Diabet Med 2003;20:119-26
   PubMed Web of Science ®Google Scholar
• Muller M, van der Graaf Y, Visseren FL, et al. Hypertension and longitudinal changes in cerebral blood flow: the SMART-MR study. Ann Neurol 2012;71:825-33
   PubMed Web of Science ®Google Scholar
• Vernooij MW, van der Lugt A, Ikram MA, et al. Total cerebral blood flow and total brain perfusion in the general population: the Rotterdam Scan Study. J Cerebr Blood Flow Metabol 2008;28:412-19
   PubMed Web of Science ®Google Scholar
• Sabayan B, Jansen S, Oleksik AM, et al. Cerebrovascular hemodynamics in Alzheimer’s disease and vascular dementia: a meta-analysis of transcranial Doppler studies. Ageing Res Rev 2012;11:271-7
   PubMed Web of Science ®Google Scholar
• Iturria-Medina Y, Sotero RC, Toussaint PJ, et al. Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nat Comm 2016;7:11934
   PubMed Web of Science ®Google Scholar
• Mizumasa T, Hirakata H, Yoshimitsu T, et al. Dialysis-related hypotension as a cause of progressive frontal lobe atrophy in chronic hemodialysis patients: a 3-year prospective study. Nephron Clin Pract 2004;97:c23-30
   PubMedGoogle Scholar
• Reising A, Sambale S, Donnerstag F, et al. Effect of isovolemic, isothermic hemodialysis on cerebral perfusion and vascular stiffness using contrast computed tomography and pulse wave velocity. PloS One 2013;8:e56396
   PubMed Web of Science ®Google Scholar
• Kok RVF. Dutch translation of the Mini Mental State Examination (2002), based on Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98
   Google Scholar
• Adunsky A, Fleissig Y, Levenkrohn S, et al. A comparative study of Mini-Mental Test, Clock Drawing task and Cognitive-FIM in evaluating functional outcome of elderly hip fracture patients. Clin Rehabil 2002;16:414-19
   PubMed Web of Science ®Google Scholar
• Suhr J, Grace J, Allen J, et al. Quantitative and qualitative performance of stroke versus normal elderly on six clock drawing systems. Arch Clin Neuropsychol 1998;13:495-502
   PubMed Web of Science ®Google Scholar
• Brand N, Jolles J. Learning and retrieval rate of words presented auditorily and visually. J Gen Psychol 1985;112:201-10
   PubMed Web of Science ®Google Scholar
• Rey A. L’examen psychologique dans les cas d’encephalopathie traumatique. Paris (France): Presses Universitaires de France, 1964
   Google Scholar
• Van der Elst W, van Boxtel MP, van Breukelen GJ, Jolles J. Rey’s verbal learning test: normative data for 1855 healthy participants aged 24–81 years and the influence of age, sex, education, and mode of presentation. J Int Neuropsychol Soc 2005;11:290-302
   PubMed Web of Science ®Google Scholar
• Stroop J. Studies of interference in serial verbal reaction. J Exp Psychol 1935;18:643-62
   Google Scholar
• Van der Elst W, Van Boxtel MP, Van Breukelen GJ, Jolles J. The Stroop color–word test: influence of age, sex, and education; and normative data for a large sample across the adult age range. Assessment 2006;13:62-79
   PubMed Web of Science ®Google Scholar
• Arnett JA, Labovitz SS. Effect of physical layout in performance of the Trail Making Test. Psychol Assess 1995;7:220-1
   Web of Science ®Google Scholar
• Schmand BHP, de Koning I. Normen voor Stroop kleur-woord tests, Trail Making test en Story Recall van de Rivermead Behavioural Memory Test. Amsterdam: Neuropsychology of the Netherlands Institute of Psychologists, 2003
   Google Scholar
• Lindeboom J, Schmand B, Tulner L, et al. Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Pschiatry 2002;73:126-33
   PubMed Web of Science ®Google Scholar
• van Hoof JJ, Jogems-Kosterman BJ, Sabbe BG, et al. Differentiation of cognitive and motor slowing in the Digit Symbol Test (DST): differences between depression and schizophrenia. J Psychiatr Res 1998;32:99-103
   PubMed Web of Science ®Google Scholar
• Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982;17:37-49
   PubMed Web of Science ®Google Scholar
• Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol Biol Med Sci 2001;56:M146-56
   PubMed Web of Science ®Google Scholar
• Kempen GI, Miedema I, Ormel J, Molenaar W. The assessment of disability with the Groningen Activity Restriction Scale. Conceptual framework and psychometric properties. Soc Sci Med 1996;43:1601-10
   PubMed Web of Science ®Google Scholar
• Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-86
   PubMed Web of Science ®Google Scholar
• VanderZee KI, Sanderman R, Heyink JW, de Haes H. Psychometric qualities of the RAND 36-Item Health Survey 1.0: a multidimensional measure of general health status. Int J Behav Med 1996;3:104-22
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
   PubMed Web of Science ®Google Scholar
• Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res 2006;60:631-7
   PubMed Web of Science ®Google Scholar
• Houx PJ, Shepherd J, Blauw GJ, et al. Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk. J Neurol Neurosurg Pschiatry 2002;73:385-9
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol 1999;84:1192-7
   PubMed Web of Science ®Google Scholar
• van Exel E, Gussekloo J, Houx P, et al. Atherosclerosis and cognitive impairment are linked in the elderly. The Leiden 85-plus Study. Atherosclerosis 2002;165:353-9
   PubMed Web of Science ®Google Scholar
• Moonen JE, Foster-Dingley JC, de Ruijter W, et al. Effect of discontinuation of antihypertensive treatment in elderly people on cognitive functioning – the DANTE study Leiden: a randomized clinical trial. JAMA Intern Med 2015;175:1622-30
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97
   PubMed Web of Science ®Google Scholar
• Sontheimer EJ, Carthew RW. Silence from within: endogenous siRNAs and miRNAs. Cell 2005;122:9-12
   PubMed Web of Science ®Google Scholar
• van Rooij E, Olson EN. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Investig 2007;117:2369-76
   PubMed Web of Science ®Google Scholar
• Leidinger P, Backes C, Deutscher S, et al. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol 2013;14:R78
   PubMed Web of Science ®Google Scholar
• Bijkerk R, Duijs JM, Khairoun M, et al. Circulating MicroRNAs associate with diabetic nephropathy and systemic microvascular damage and normalize after simultaneous pancreas–kidney transplantation. Am J Transplant 2015;15:1081-90
   PubMed Web of Science ®Google Scholar
• Guay C, Regazzi R. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol 2013;9:513-21
   PubMed Web of Science ®Google Scholar
• Kielstein JT, Fliser D. The past, presence and future of ADMA in nephrology. Nephrologie Therapeutique 2007;3:47-54
   PubMed Web of Science ®Google Scholar
• Ueda S, Yamagishi S, Matsumoto Y, et al. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin Exp Nephrol 2007;11:115-21
   PubMedGoogle Scholar
• Zoccali C. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens 2006;24:611-19
   PubMed Web of Science ®Google Scholar
• Lentz SR, Rodionov RN, Dayal S. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. Atherosclerosis Suppl 2003;4:61-5
   PubMed Web of Science ®Google Scholar
• Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5
   PubMed Web of Science ®Google Scholar
• Pecchini P, Malberti F, Mieth M, et al. Measuring asymmetric dimethylarginine (ADMA) in CKD: a comparison between enzyme-linked immunosorbent assay and liquid chromatography–electrospray tandem mass spectrometry. J Nephrol 2012;25:1016-22
   PubMed Web of Science ®Google Scholar
• Chang FC, Lai TS, Chiang CK, et al. Angiopoietin-2 is associated with albuminuria and microinflammation in chronic kidney disease. PLoS One 2013;8:e54668
   PubMed Web of Science ®Google Scholar
• Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006;27:552-8
   PubMed Web of Science ®Google Scholar
• Brindle NP, Saharinen P, Alitalo K. Signaling and functions of angiopoietin-1 in vascular protection. Circulation Res 2006;98:1014-23
   PubMed Web of Science ®Google Scholar
• David S, John SG, Jefferies HJ, et al. Angiopoietin-2 levels predict mortality in CKD patients. Nephrol Dial Transplant 2012;27:1867-72
   PubMed Web of Science ®Google Scholar
• David S, Kumpers P, Hellpap J, et al. Angiopoietin 2 and cardiovascular disease in dialysis and kidney transplantation. Am J Kidney Dis 2009;53:770-8
   PubMed Web of Science ®Google Scholar
• Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006;114:597-605
   PubMed Web of Science ®Google Scholar
• Larsson M, Favilla R, Stromberg T. Assessment of advanced glycated end product accumulation in skin using auto fluorescence multispectral imaging. Comput Biol Med 2016;85:106-111
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circulation Res 1999;84:489-97
   PubMed Web of Science ®Google Scholar
• McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW. Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. Clin J Am Soc Nephrol 2011;6:2356-63
   PubMed Web of Science ®Google Scholar
• Meerwaldt R, Graaff R, Oomen PH, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004;47:1324-30
   PubMed Web of Science ®Google Scholar